Debut Plus

₹275.35

▼ -0.41 -0.15%

16 Jul 2026

NSE Listed

Marksans Pharma Limited (MARKSANS)

Volume: 17,13,848Avg Vol 1W: 17,31,962.4Avg Vol 1M: 18,78,347.8552W Range:₹155₹281.6
NSE BSE www.marksanspharma.com
Key Ratios
Checked 15h ago
Market Cap₹12,496 Cr
Current Price₹275.35
Previous Close₹275.76
High / Low (52w)₹281.6 / ₹155
Volume17,13,848
Avg Vol (1W)17,31,962.4
Avg Vol (1M)18,78,347.85
Stock P/E84.33
Book Value₹66.71
Dividend Yield0.4%
ROE13.8%
ROA10.9%
Revenue (TTM)₹2,693 Cr
Revenue Growth20.5%
Profit Margin14.2%
Total Debt₹0 Cr
Shares Outstanding45 Cr
Face Value₹1
EPS (TTM)₹3.27
P/B4.13
Debt / Equity0.11
50 DMA₹249.26
200 DMA₹196.82
Day change-0.15%
Price Chart
₹275.35▲ 5.48% · 1Y
₹277₹1573.8Cr
2025-07-16
2026-07-15

20-day avg volume: 18.8L shares

Pros
  • Company is almost debt-free.
Cons
  • Stock trades at a high P/E of 84.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹591 Cr₹642 Cr₹682 Cr₹708 Cr₹620 Cr₹720 Cr₹754 Cr₹856 Cr
EBITDA₹123 Cr₹127 Cr₹146 Cr₹120 Cr₹83 Cr₹139 Cr₹157 Cr₹206 Cr
Net Profit₹89 Cr₹97 Cr₹105 Cr₹91 Cr₹58 Cr₹98 Cr₹113 Cr₹148 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹921 Cr₹1,005 Cr₹1,135 Cr₹1,383 Cr₹1,533 Cr₹1,911 Cr₹2,228 Cr₹2,693 Cr
EBITDA₹60 Cr₹114 Cr₹166 Cr₹310 Cr₹256 Cr₹347 Cr₹435 Cr₹516 Cr
Net Profit₹33 Cr₹76 Cr₹121 Cr₹236 Cr₹185 Cr₹266 Cr₹314 Cr₹381 Cr
EPS0.81.872.955.764.516.416.928.4
Balance Sheet
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹732 Cr₹804 Cr₹903 Cr₹1,229 Cr₹1,640 Cr₹2,190 Cr₹2,681 Cr₹3,240 Cr
Total Liabilities₹252 Cr₹251 Cr₹254 Cr₹323 Cr₹417 Cr₹425 Cr₹595 Cr₹750 Cr
Equity₹480 Cr₹553 Cr₹649 Cr₹905 Cr₹1,223 Cr₹1,765 Cr₹2,086 Cr₹2,489 Cr
Total Debt————————
Cash Flow
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹58 Cr₹54 Cr₹258 Cr₹227 Cr₹172 Cr₹300 Cr₹353 Cr₹333 Cr
Investing₹-39 Cr₹-13 Cr₹-60 Cr₹-45 Cr₹-84 Cr₹-259 Cr₹-141 Cr₹-49 Cr
Financing₹3 Cr₹-21 Cr₹-114 Cr₹-15 Cr₹80 Cr₹198 Cr₹-69 Cr₹-65 Cr
Free Cash Flow₹58 Cr₹54 Cr₹258 Cr₹227 Cr₹172 Cr₹300 Cr₹353 Cr₹333 Cr
Efficiency & Working Capital
ROCE17.4%
Interest Coverage44.2
Dividend Payout—
Debtor Days75 d
Inventory Days118 d
Payable Days43 d
Cash Conversion Cycle150 d
Working Capital Days193 d
Shareholding Details

As of 2026-03-31

Promoter43.9%
FII16.8%
DII6.6%
Institutions23.3%
Public32.8%
Promoter Pledge0%
No. of Shareholders2,46,279
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodJun 2023Sept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Promoters43.8%43.8%43.8%43.8%43.9%43.9%43.9%43.9%43.9%43.9%43.9%43.9%
FIIs14.9%15.1%15.6%15.6%18.6%21.3%22%22.2%19.9%16.9%8.1%16.8%
DIIs3.7%3.1%3.8%5.2%3.7%4.1%4.3%4.6%5.5%5.3%5.9%6.6%
Public37.6%37.9%36.8%35.4%33.8%30.7%29.9%29.4%30.7%33.9%42.1%32.8%
Promoter Pledge0%0%0%0%0%0%0%0%0%0%0%0%
No. of Shareholders1,88,4472,07,9372,37,3772,54,6992,35,5002,48,8452,59,8132,57,2732,56,2212,65,7882,55,1532,46,279
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503————
Major Shareholders (>1%)
NameCategoryStakeShares
Mark SaldanhaShareholding of Promoter and Promoter Group43.8%19.85 Cr
Orbimed Asia Iv Mauritius Fvci LimitedPublic Shareholding8.6%3.91 Cr
Uti-healthcare FundPublic Shareholding2.5%1.13 Cr
Kotak Mahindra Trustee Co Ltd A/c Kotak Special Opportunities FundPublic Shareholding1.1%51,27,836
Sandra SaldanhaShareholding of Promoter and Promoter Group0.1%3,30,456
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Mark Saldanha00%2026-03-31
Sandra Saldanha00%2026-03-31
Kotak Mahindra Trustee Co Ltd A/c Kotak Special Opportunities Fund00%2026-03-31
Uti-healthcare Fund00%2026-03-31
Orbimed Asia Iv Mauritius Fvci Limited00%2026-03-31
Mark Saldanha00%2025-12-31
Sandra Saldanha00%2025-12-31
Uti-healthcare Fund00%2025-12-31
Kotak Mahindra Trustee Co Ltd A/c Kotak Special Opportunities Fund00%2025-12-31
Orbimed Asia Iv Mauritius Fvci Limited00%2025-12-31
Mark Saldanha00%2025-09-30
Sandra Saldanha00%2025-09-30
Board of Directors
NameDesignationYear
Mark SaldanhaChairman & Managing Director2025
Harshavardhan PanigrahiCompany Sec. & Compli. Officer2025
Sandra SaldanhaWhole-time Director2025
Digant Mahesh ParikhIndependent Director2025
Varddhman Vikramaditya JainWhole-time Director2025
Abhinna Sundar MohantyIndependent Director2025
Sunny SharmaNon Executive Director2025
Shailaja VardhanIndependent Director2025
Srinivas MishraIndependent Director2025
Segments — Product
SegmentRevenueShare
Pharmaceuticals₹0 Cr—
Segments — Geography
RegionRevenueShare
US & North America₹732 Cr62.3%
Europe and UK₹293 Cr24.9%
Australia and New Zealand₹51 Cr4.4%
Local₹0 Cr0%
Rest of World₹98 Cr8.4%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹1554545
Corporate Actions
TypeDateValueRemark
dividend2025-08-01₹0.8 (80%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
20251,057001301,069
2025000000
202530013016
Insider / Designated-Person Trades

9 recent disclosure(s)

Sandra SaldanhaAcquisition · 63,276
Sandra SaldanhaAcquisition · 47,000
Arvind SinghDisposal · 2,000
Arvind SinghDisposal · 3,000
Arvind SinghDisposal · 6,500
Arvind SinghAcquisition · 3,000
Substantial Acquisitions (SAST)

1 disclosure(s)

Market11/06/2025 · 1,02,73,443
Company Information
Incorporated1992
ChairmanMark Saldanha
AuditorMSKA & Associates
Investor Email[email protected] ; info@marksan
🌐 www.marksanspharma.com ↗

📍 11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Marc Technocrats LimitedMarco Cable & Conductor LimitedMarico LimitedMarine Electrical (I) Ltd.Marinetrans India LimitedMarkolines Pavement Tec LimitedMarsons LimitedMarushika Technology Ltd.Maruti Suzuki India Ltd.MAS Financial Serv Ltd.Mask Investments LimitedMason Infratech LimitedAll “M” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search